SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

Advanced Micro Devices is trending as investors aggressively rotate into CPU-related AI plays following positive sector sentiment and optimistic analyst upgrades. The community is sharply divided, with bulls pointing to long-term secular growth and infrastructure dominance while bearish traders voice concerns over extreme valuation multiples, extended RSI levels, and the sustainability of this rapid parabolic move.

Dumb SEND IT

Dumb SEND IT ($DSIT) is gaining significant traction as a community-driven meme project that emphasizes rapid, collective "sending" to build momentum toward its market cap goals. The community is heavily focused on HODLing through volatility, active promotion to onboard new degens, and community-wide airdrops to reward early supporters as they aim to hit key milestones.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is currently surging due to the FDA lifting the clinical hold on its Phase 3 MAGNITUDE trial, signaling a significant derisking of its CRISPR-based heart disease therapy. Community discussion is dominated by bullish sentiment regarding the potential for a major short squeeze, as participants highlight the stock's high short interest and the significant valuation gap remaining since the trial's original halt.

"What's Updog?" is a Community Led token.

UpDog

UpDog is capturing attention through a combination of sustained community momentum, aggressive whale accumulation, and successful organic growth efforts that have kept the token trending. Investors are actively discussing the project's multi-year history on Solana and its presence on the Jupiter strict list, with many looking for the next major leg up in its market trajectory.

Terra is a decentralized financial payment network that rebuilds the traditional payment stack on the blockchain. Luna is the reserve currency of the Terra platform. It has three core functions: i) mine Terra transactions through staking, ii) ensure the price stability of Terra stablecoins and iii) provide incentives for the platform’s blockchain validators.

Terra Luna Classic

Terra Luna Classic is experiencing heightened market attention as community members speculate on potential supply burns and project revivals while actively monitoring upcoming clarity legislation. Investors are engaging in spirited discussions regarding the token's long-term utility, with many holding positions in anticipation of a significant price reversal.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is trending as a major retail and momentum favorite, fueled by significant investor enthusiasm over potential partnerships with hyperscalers and its role in AI data center infrastructure. The community is heavily focused on a potential short squeeze, given the intense trading volume and reports of restricted share availability, while debates persist between optimistic long-term holders and bearish concerns regarding the company's current revenue levels.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is seeing a historic surge, fueled by an earnings beat that shifted investor sentiment on the role of CPUs in AI infrastructure and triggered a massive short squeeze. The community is actively debating the sustainability of this parabolic move, with many traders watching closely for a potential pullback while bulls point to new foundry partnerships and deep-pocketed institutional backing as evidence of a long-term turnaround.

Atomera, Inc. engages in the development, commercialization, and licensing of proprietary processes and technologies for the semiconductor industry. It developed Mears Silicon Technology, which increases performance and power efficiency in semiconductor transistors. The company was founded by Robert Mears on November 26, 2001 and is headquartered in Los Gatos, CA.

Atomera Inc

Atomera Inc. is trending as investors aggressively speculate on imminent partnership announcements following a series of technical advancements in semiconductor materials. Community sentiment is deeply divided between long-term supporters anticipating a major licensing breakthrough and vocal critics expressing skepticism over the firm's long-standing lack of commercial revenue.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomm is seeing heightened investor attention as the semiconductor sector navigates the complex intersection of AI-driven demand and supply-side constraints. Community discussions are centered on the company's long-term potential in edge AI and automotive markets versus short-term concerns regarding memory shortages and shifting handset industry dynamics.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk is experiencing a massive rally driven by insatiable AI data center demand for high-performance NAND flash memory and anticipation surrounding its upcoming earnings. The community is actively tracking a potential stock split, while retail investors remain locked in a heated debate between holding for further parabolic gains and betting on an inevitable correction.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>A takeover or a large partnership was reportedly on the table for the company.</li><li>According to a report from Seeking Alpha, citing Stat News, the nature of the potential agreement, while unclear, is one of “significant scope.”&nbsp;</li><li>Moderna has been seeking to expand its portfolio since COVID-19 infections dropped globally. &nbsp;</li></ul>Shares of Moderna (MRNA) jumped 17% on Thursday afternoon following reports that the company held talks with at least one large drugmaker.According to a <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://seekingalpha.com/news/4511489-moderna-gains-on-report-it-held-talks-with-at-least-one-large-drugmaker">report</a> from Seeking Alpha, citing Stat News, a takeover or a large partnership was being considered for the company. The nature of the potential agreement, while unclear, is one of “significant scope,” the report added. &nbsp;<h2 class="st-heading-2">Moderna’s Weakening Sales</h2>In August, the vaccine maker lowered its full-year revenue guidance to a range of $1.5 billion to $2.2 billion, reflecting a $300 million reduction at the high end of the range.For the second quarter, the company reported revenues of $142 million, down from the $241 million reported in the corresponding quarter of 2024. The company attributed the revenue drop to lower COVID-19 vaccine sales. It noted that its demand is expected to be concentrated in the second half of the year, aligning with the fall and winter seasons, due to the seasonal nature of the infection.Sales of Moderna’s COVID-19 vaccine came in at $114 million in the three months through the end of June, while its Respiratory Syncytial Virus vaccine sales were negligible.The company has been seeking to expand its portfolio since COVID-19 infections dropped globally from their peak in the early 2020s. The company hit a peak yearly revenue of $19.3 billion in 2022, when COVID-19 &nbsp;infections were high, which then dropped to $3.2 billion in 2024. The shares have borne the brunt, dropping over 57% in the past five years.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment about <a href="https://stocktwits.com/symbol/MRNA">MRNA stock</a> jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.A Stocktwits user sounded cautious about the company’s upcoming earnings.<stembedurl>https://stocktwits.com/Galba/message/634362215</stembedurl>Since the start of the year, the company’s shares have declined by approximately 30%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/bmy-ceo-expects-cancer-drug-opdivo-to-drive-strong-sales-in-2025/cLG8bFRR3xp">BMY CEO Expects Cancer Drug Opdivo To Drive Strong Sales In 2025</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Moderna headquarters, exterior view, Cambridge, Massachusetts, USA. (Photo by: Plexi Images/GHI/UCG/Universal Images Group via Getty Images)

Moderna Stock Rallies On Reports Of Company Entering Talks With A Drugmaker For A Potential Deal

According to a report from Seeking Alpha, citing Stat News, Moderna has held talks with at least one large drugmaker. 

GPIX
Goldman Sachs ETF Trust - Goldman Sachs S&P 500 Core Premium Income ETF

Feed

News

Sentiment

Fundamentals

Info

Latest GPIX News

GPIXGoldman Sachs ETF Trust - Goldman Sachs S&P 500 Core Premium Income ETF